Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Pancreatic Neoplasms

ClinicalTrials.gov lists 3,869 trials for Pancreatic Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 125.

MeSH D010190 Neoplasms Neoplasm C04 C06 C19
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 790 Phase 1/2 Phase 1/2 380 Phase 2 Phase 2 907 Phase 2/3 Phase 2/3 44 Phase 3 Phase 3 183 Phase 4 Phase 4 48 Not applicable Not applicable 718 Observational Observational 781 Phase 1 Phase 1 790 Phase 1/2 Phase 1/2 380 Phase 2 Phase 2 907 Phase 2/3 Phase 2/3 44 Phase 3 Phase 3 183 Phase 4 Phase 4 48 Not applicable Not applicable 718 Observational Observational 781

Trials per phase (log scale)

1 more section with rows

3,664 of the 3,869 trials are tagged with Pancreatic Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Pancreatic Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Pancreatic Neoplasms trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 245

1990: 1 trials (Observational 1) 1991: 2 trials (Observational 1, Phase 2 1) 1992: 1 trials (Observational 1) 1994: 2 trials (Observational 1, Phase 1 1) 1995: 4 trials (Phase 2 2, Phase 1 2) 1996: 5 trials (Phase 2 4, Phase 1 1) 1997: 12 trials (Phase 3 2, Phase 2 3, Phase 1/2 2, Phase 1 5) 1998: 22 trials (Phase 3 3, Phase 2 6, Phase 1 13) 1999: 28 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 20, Phase 1 3) 2000: 31 trials (Observational 7, Not applicable 1, Phase 3 3, Phase 2 7, Phase 1/2 2, Phase 1 11) 2001: 37 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 10, Phase 2 12, Phase 1/2 2, Phase 1 8) 2002: 40 trials (Observational 6, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 19, Phase 1/2 1, Phase 1 8) 2003: 54 trials (Observational 2, Not applicable 4, Phase 3 5, Phase 2/3 2, Phase 2 31, Phase 1/2 4, Phase 1 6) 2004: 65 trials (Observational 12, Not applicable 2, Phase 4 1, Phase 3 6, Phase 2/3 2, Phase 2 22, Phase 1/2 7, Phase 1 13) 2005: 69 trials (Observational 6, Not applicable 4, Phase 4 1, Phase 3 4, Phase 2/3 4, Phase 2 31, Phase 1/2 6, Phase 1 13) 2006: 107 trials (Observational 12, Not applicable 10, Phase 4 2, Phase 3 12, Phase 2/3 1, Phase 2 42, Phase 1/2 8, Phase 1 20) 2007: 110 trials (Observational 21, Not applicable 9, Phase 4 3, Phase 3 7, Phase 2/3 1, Phase 2 33, Phase 1/2 8, Phase 1 28) 2008: 96 trials (Observational 21, Not applicable 9, Phase 4 2, Phase 3 4, Phase 2 28, Phase 1/2 11, Phase 1 21) 2009: 101 trials (Observational 13, Not applicable 14, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 27, Phase 1/2 14, Phase 1 26) 2010: 85 trials (Observational 17, Not applicable 10, Phase 4 2, Phase 3 4, Phase 2 26, Phase 1/2 6, Phase 1 20) 2011: 124 trials (Observational 14, Not applicable 20, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 37, Phase 1/2 8, Phase 1 37) 2012: 109 trials (Observational 18, Not applicable 28, Phase 4 3, Phase 3 5, Phase 2/3 2, Phase 2 25, Phase 1/2 9, Phase 1 19) 2013: 143 trials (Observational 28, Not applicable 29, Phase 4 4, Phase 3 5, Phase 2 28, Phase 1/2 11, Phase 1 38) 2014: 138 trials (Observational 27, Not applicable 28, Phase 4 2, Phase 3 11, Phase 2/3 3, Phase 2 30, Phase 1/2 9, Phase 1 28) 2015: 153 trials (Observational 31, Not applicable 31, Phase 4 1, Phase 3 10, Phase 2/3 2, Phase 2 30, Phase 1/2 15, Phase 1 33) 2016: 187 trials (Observational 35, Not applicable 53, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 2 31, Phase 1/2 19, Phase 1 38) 2017: 181 trials (Observational 37, Not applicable 41, Phase 4 1, Phase 3 2, Phase 2/3 2, Phase 2 42, Phase 1/2 22, Phase 1 34) 2018: 171 trials (Observational 45, Not applicable 32, Phase 4 3, Phase 3 8, Phase 2/3 3, Phase 2 30, Phase 1/2 21, Phase 1 29) 2019: 203 trials (Observational 51, Not applicable 49, Phase 4 3, Phase 3 2, Phase 2 41, Phase 1/2 20, Phase 1 37) 2020: 212 trials (Observational 53, Not applicable 54, Phase 4 4, Phase 3 5, Phase 2/3 2, Phase 2 43, Phase 1/2 17, Phase 1 34) 2021: 219 trials (Observational 59, Not applicable 41, Phase 4 2, Phase 3 6, Phase 2/3 1, Phase 2 38, Phase 1/2 26, Phase 1 46) 2022: 236 trials (Observational 66, Not applicable 54, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 35, Phase 1/2 25, Phase 1 51) 2023: 210 trials (Observational 44, Not applicable 48, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 42, Phase 1/2 21, Phase 1 45) 2024: 245 trials (Observational 50, Not applicable 48, Phase 3 8, Phase 2/3 6, Phase 2 54, Phase 1/2 27, Phase 1 52) 2025: 205 trials (Observational 46, Not applicable 38, Phase 4 2, Phase 3 13, Phase 2/3 5, Phase 2 46, Phase 1/2 23, Phase 1 32)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 212
2025 205
2024 245
2023 210
2022 236
2021 219
2020 212
2019 203
2018 171
2017 181

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 240 trials starting in 2026 and about 220 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 528 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 2,067 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Pancreatic Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 790
Phase 1/2 380
Phase 2 907
Phase 2/3 44
Phase 3 183
Phase 4 48
Not applicable 718
Observational 781
Expanded access 18

How many Pancreatic Neoplasms trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 197
Recruiting 619
Enrolling by invitation 17
Active, not recruiting 235
Available 7

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Pancreatic Neoplasms trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 125
Eli Lilly and Company 27

Which drugs are being tested for Pancreatic Neoplasms? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
NAB paclitaxel 199
OXALIPLATIN 116
"Capecitabine" 112
Calcium Leucovorin 82
Irinotecan 81

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Gemcitabine/Gemzar 556
Fluorouracile 134
Radiation Therapy 74
Cisplatin 1 67
1- Erlotinib 59

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Pancreatic Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Vomiting 913 195
Abdominal pain 911 164
Nausea 755 178
Pyrexia 738 94
Sepsis 651 163

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Pancreatic Neoplasms? (3,133)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future. CA: a cancer journal for clinicians 2026 Yes
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial. Lancet (London, England) 2026 Yes
Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Gastroenterology 2026 Yes
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216). British journal of cancer 2026 Yes
Laparoscopic duodenum-preserving total pancreatic head resection for benign and low-grade malignant tumors close to the accessory papilla (a case series). Surgical endoscopy 2026 Yes

Showing 5 of 3,133 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (10)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Rare carcinoma of pancreas Point prevalence 1-9 / 100 000 Worldwide Not stated Exact
Rare carcinoma of pancreas Point prevalence 1-5 / 10 000 Europe Not stated Exact
Rare carcinoma of pancreas Lifetime prevalence 1-9 / 100 000 Europe Not stated Exact
Rare carcinoma of pancreas Point prevalence 1-9 / 100 000 Worldwide Not stated Exact
Rare carcinoma of pancreas Point prevalence 1-5 / 10 000 Europe Not stated Exact

Showing 5 of 10 prevalence observations.

Start your 14-day trial Email me all 10 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Rare carcinoma of pancreas 217074 Exact Orphadata Science knowledge files, Product 1
Rare carcinoma of pancreas 217074 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages